590 related articles for article (PubMed ID: 18286234)
1. The tyrosine phosphatase Shp2 (PTPN11) in cancer.
Chan G; Kalaitzidis D; Neel BG
Cancer Metastasis Rev; 2008 Jun; 27(2):179-92. PubMed ID: 18286234
[TBL] [Abstract][Full Text] [Related]
2. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
3. The role of Shp2 (PTPN11) in cancer.
Mohi MG; Neel BG
Curr Opin Genet Dev; 2007 Feb; 17(1):23-30. PubMed ID: 17227708
[TBL] [Abstract][Full Text] [Related]
4. The tyrosine phosphatase Shp2 in development and cancer.
Grossmann KS; Rosário M; Birchmeier C; Birchmeier W
Adv Cancer Res; 2010; 106():53-89. PubMed ID: 20399956
[TBL] [Abstract][Full Text] [Related]
5. [The Biological Function of SHP2 in Human Disease].
Li SM
Mol Biol (Mosk); 2016; 50(1):27-33. PubMed ID: 27028808
[TBL] [Abstract][Full Text] [Related]
6. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.
Mohi MG; Williams IR; Dearolf CR; Chan G; Kutok JL; Cohen S; Morgan K; Boulton C; Shigematsu H; Keilhack H; Akashi K; Gilliland DG; Neel BG
Cancer Cell; 2005 Feb; 7(2):179-91. PubMed ID: 15710330
[TBL] [Abstract][Full Text] [Related]
7. PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.
Maheshwari M; Belmont J; Fernbach S; Ho T; Molinari L; Yakub I; Yu F; Combes A; Towbin J; Craigen WJ; Gibbs R
Hum Mutat; 2002 Oct; 20(4):298-304. PubMed ID: 12325025
[TBL] [Abstract][Full Text] [Related]
8. Noonan syndrome, the Ras-MAPK signalling pathway and short stature.
Binder G
Horm Res; 2009 Apr; 71 Suppl 2():64-70. PubMed ID: 19407499
[TBL] [Abstract][Full Text] [Related]
9. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
[TBL] [Abstract][Full Text] [Related]
10. PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.
Ogata T; Yoshida R
Pediatr Endocrinol Rev; 2005 Jun; 2(4):669-74. PubMed ID: 16208280
[TBL] [Abstract][Full Text] [Related]
11. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Chen Y; Takita J; Hiwatari M; Igarashi T; Hanada R; Kikuchi A; Hongo T; Taki T; Ogasawara M; Shimada A; Hayashi Y
Genes Chromosomes Cancer; 2006 Jun; 45(6):583-91. PubMed ID: 16518851
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.
Tartaglia M; Niemeyer CM; Fragale A; Song X; Buechner J; Jung A; Hählen K; Hasle H; Licht JD; Gelb BD
Nat Genet; 2003 Jun; 34(2):148-50. PubMed ID: 12717436
[TBL] [Abstract][Full Text] [Related]
13. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
Araki T; Mohi MG; Ismat FA; Bronson RT; Williams IR; Kutok JL; Yang W; Pao LI; Gilliland DG; Epstein JA; Neel BG
Nat Med; 2004 Aug; 10(8):849-57. PubMed ID: 15273746
[TBL] [Abstract][Full Text] [Related]
14. A novel PTPN11 mutation in LEOPARD syndrome.
Conti E; Dottorini T; Sarkozy A; Tiller GE; Esposito G; Pizzuti A; Dallapiccola B
Hum Mutat; 2003 Jun; 21(6):654. PubMed ID: 14961557
[TBL] [Abstract][Full Text] [Related]
15. Germline gain-of-function mutations in SOS1 cause Noonan syndrome.
Roberts AE; Araki T; Swanson KD; Montgomery KT; Schiripo TA; Joshi VA; Li L; Yassin Y; Tamburino AM; Neel BG; Kucherlapati RS
Nat Genet; 2007 Jan; 39(1):70-4. PubMed ID: 17143285
[TBL] [Abstract][Full Text] [Related]
16. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.
Miyamoto D; Miyamoto M; Takahashi A; Yomogita Y; Higashi H; Kondo S; Hatakeyama M
Oncogene; 2008 Jun; 27(25):3508-15. PubMed ID: 18223690
[TBL] [Abstract][Full Text] [Related]
17. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.
Chan RJ; Feng GS
Blood; 2007 Feb; 109(3):862-7. PubMed ID: 17053061
[TBL] [Abstract][Full Text] [Related]
18. Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
Jopling C; van Geemen D; den Hertog J
PLoS Genet; 2007 Dec; 3(12):e225. PubMed ID: 18159945
[TBL] [Abstract][Full Text] [Related]
19. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
[TBL] [Abstract][Full Text] [Related]
20. Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Liu X; Zheng H; Li X; Wang S; Meyerson HJ; Yang W; Neel BG; Qu CK
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):984-9. PubMed ID: 26755576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
